Shanghai Hospital Pioneers Advanced Prostate Cancer Therapy with Pluvicto
Shanghai Pudong Hospital has administered the first dose in the city of lutetium-177 vipivotide tetraxetan (Pluvicto), a groundbreaking treatment for advanced metastatic prostate cancer. This milestone signifies a major step forward in precision oncology for Chinese patients, offering renewed hope for those who have exhausted conventional treatment options.
The Promise of Targeted Radionuclide Therapy
Pluvicto represents a novel approach to cancer treatment known as theranostics – combining diagnostics and therapy. The treatment precisely targets prostate cancer cells by utilizing a molecule, PSMA (prostate-specific membrane antigen), found on their surface. Radioactive molecules bind to PSMA, delivering radiation directly to the cancer cells while minimizing damage to surrounding healthy tissues.
Approved by China’s National Medical Products Administration (NMPA) in November 2025, Pluvicto is currently the only PSMA-targeted radioligand therapy available in China. This approval expands treatment possibilities for patients whose prostate cancer has spread and progressed despite hormonal therapies and chemotherapy.
A Growing Need for Advanced Prostate Cancer Treatments
Prostate cancer is a significant health concern for men in China, with incidence rates continuing to climb. Unfortunately, many patients are diagnosed at an advanced stage, limiting the effectiveness of standard interventions. This modern therapy aims to address this critical gap in care.
According to Dr. Liu Xingdang, director of the hospital’s nuclear medicine department, “This therapy introduces precise targeting for prostate cancer cure… Multiple international clinical studies have confirmed it can significantly delay disease progression, extend survival, and improve quality of life.”
Pudong’s Emerging Role in Precision Oncology
The Pudong New Area is actively fostering an integrated industry focused on innovative targeted isotopes for both diagnosis and treatment. Its strategic location – a short drive from Pudong International Airport – coupled with supportive policies, positions the hospital to attract both domestic and international patients seeking this advanced therapy.
Medical Tourism and Cost-Effectiveness
Pluvicto is imported to meet doctor’s prescriptions. The hospital is actively developing an international consultation and liaison platform for overseas patients. A key advantage for international patients is the cost; treatment is estimated to be 60 to 70 percent less expensive than in Western countries, requiring only a single day of hospitalization. The treatment is also covered by commercial medical insurance.
Future Trends in Targeted Cancer Therapies
The introduction of Pluvicto in China signals a broader trend towards precision oncology and targeted radionuclide therapies. Expect to see increased investment in research and development of similar treatments for other cancers, focusing on identifying unique biomarkers for precise targeting. The success of Pudong Hospital’s program could serve as a model for other hospitals across China and beyond.
the integration of artificial intelligence (AI) in identifying suitable candidates for these therapies, analyzing PSMA PET scans, and optimizing treatment plans will likely accelerate. The development of more efficient and cost-effective isotope production methods will also be crucial for wider accessibility.
FAQ
What is Pluvicto used for? Pluvicto is used to treat advanced metastatic prostate cancer that has progressed after other treatments.
What is PSMA? PSMA (prostate-specific membrane antigen) is a molecule found on the surface of prostate cancer cells, used to target the therapy.
Is Pluvicto available to international patients? Yes, Pudong Hospital has established an international consultation platform for overseas patients.
How long does treatment with Pluvicto seize? Treatment typically requires only a single day of hospitalization.
Is Pluvicto covered by insurance? Pluvicto is covered by commercial medical insurance.
Did you know? A PSMA PET scan is required to determine if a patient is suitable for Pluvicto treatment.
Pro Tip: Early diagnosis is crucial for effective prostate cancer treatment. Regular check-ups and screenings are highly recommended.
Have questions about Pluvicto or prostate cancer treatment options? Share your thoughts in the comments below!
